A Phase 2 interventional study of Mirikizumab and Placebo in Crohn's Disease, sponsored by Eli Lilly and Company. Completed at 108 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-30.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.
Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 4th largest by enrollment, is the only one that started in 2016, is the only one in phase 2, and was the 1st registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
Alimentiv Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–17
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
This study's enrollment of 191 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 150 across the 10 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Crohn Disease by Eli Lilly and Company: 6 open now, 7 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 1st registered.
Eli Lilly and Company’s Crohn Disease studies by the year they started, since 2016.
2 of the studies testing mirikizumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06997965Alimentiv Inc.Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | 2027-09-01 |
| NCT07292012Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEfficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing mirikizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 10 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 (Weeks 0 -12): 200 Milligram (mg), 600 mg, and 1000 mg mirikizumab administered intravenously (IV) every 4 Weeks (Q4W). Period 2 (Weeks 12 - 52): 200 mg, 600 mg, and 1000 mg mirikizumab administered IV Q4W; 300 mg mirikizumab administered subcutaneously (SC) Q4W; 1000 mg mirikizumab administered IV Q4W for non-improvers in period 1; and 1000 mg mirikizumab administered IV Q4W for participants on placebo during period 1. Period 3 (Weeks 52 - 208): 300 mg mirikizumab administered SC Q4W.
Drug: Mirikizumab
Period 1 (Weeks 0 -12): Participants received placebo administered intravenously (IV) Q4W.
Drug: Placebo
Also known as: LY3074828
Percentage of Participants Achieving Endoscopic Response at Week 12
Endoscopic response defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12. The SES-CD evaluates 4 endoscopic variables: presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis. The total SES-CD calculated as sum of 4 variables for 5 bowel segments: (ileum;right,transverse,and left colon;and rectum): presence and size of ulcers (none = score 0; diameter 0.1-0.5 cm = score 1; 0.5-2 cm = score 2; \>2 cm = score 3); extent of ulcerated surface (none = 0; \<10% = 1;10-30% = 2;\>30% = 3);extent of affected surface (none = 0; \<50% = 1;50-75% = 2;\>75% =3); and presence and type of narrowings (none=0; single, can be passed=1; multiple,can be passed=2; cannot be passed=3). Total SES-CD scores range from 0 to 56, with higher scores indicating more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Endoscopic Remission at Week 12
Endoscopic remission defined as SES-CD of \<4 ileal-colonic or \<2 for isolated ileal disease, and no subscore \>1 at week 12. The SES-CD evaluates 4 endoscopic variables: presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: (ileum; right, transverse, and left colon; and rectum): presence and size of ulcers (none = score 0; diameter 0.1-0.5 cm = score 1; 0.5-2 cm = score 2; greater than (\>) 2 cm = score 3); extent of ulcerated surface (none = 0; less than (\<) 10% = 1; 10-30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50-75% = 2; \>75% = 3); and presence and type of narrowings (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total SES-CD scores range from 0 to 56, with higher scores indicating more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Patient Reported Outcome Remission at Week 12
PRO remission is defined as stool frequency (SF) ≤2.5 and abdominal pain (AP) ≤1 and no worse than baseline at week 12. SF captures the number of liquid or very soft stools. AP score is classified as 0=none, 1=mild, 2=moderate, 3=severe.
Time frame: Week 12
Mean Change From Baseline on the Patient Global Rating - Severity (PGRS) Crohn's Disease Score at Week 12
The PGRS is a 1-item patient-rated questionnaire designed to assess the participant's rating of their disease symptom severity over the past 24 hours. Responses are graded on a 6-point scale in which a score of 1 indicates the subject has no symptoms (that is, "none") and a score of 6 indicates that the participant's symptom are "very severe." Least Squares Mean (LS Mean) was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Time frame: Baseline, Week 12
Mean of Patient Global Rating - Change (PGRC) Crohn's Disease Score at Week 12
The PGRC scale is a patient-rated instrument designed to assess the participant's rating of change in their symptom(s). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the participant's symptom is "very much better," a score of 4 indicates that the participant's symptom has experienced "no change," and a score of 7 indicates that the participant's symptom is "very much worse."
Time frame: Baseline, Week 12
Mean Change From Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 12
The IBDQ is a 32-item self-administered questionnaire. The IBDQ has 4 dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Time frame: Baseline, Week 12
Mean Change From Baseline on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0-4 associated with a range over "Not at all" to "Very much" for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Time frame: Baseline, Week 12
Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Week 12
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains:physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
Time frame: Baseline, Week 12
Population Pharmacokinetics (PopPK): Mean Population Clearance of Mirikizumab
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance. Clearance is estimated based on concentration data collected in the time frame of 0-208 weeks.
Time frame: Week 0, 4, 8: Predose, end of infusion; Week 2; 4; 6; 8, 11-12; 12-13; 16; 20; 24; 28; 36; 44; 52; 60; 68; 76; 84; 92; 104; 108; 112; 120; 128; 136; 144; 156; 164; 172; 180; 188; 196 and 208 weeks post infusion
Population Pharmacokinetics (PopPK): Mean Population Volume of Distribution of Mirikizumab
Population mean (between-subject coefficient variance \[CV %\]) apparent volume of distribution. Volume of distribution is estimated based on concentration data collected in the time frame of 0-208 weeks.
Time frame: Week 0, 4, 8: Predose, end of infusion; Week 2; 4; 6; 8, 11-12; 12-13; 16; 20; 24; 28; 36; 44; 52; 60; 68; 76; 84; 92; 104; 108; 112; 120; 128; 136; 144; 156; 164; 172; 180; 188; 196 and 208 weeks post infusion
| Milestone | Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | Period 1: 600 mg Mirikizumab IV Q4W | Period 1: 1000 mg Mirikizumab IV Q4W | Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | Period 3: 300 mg Mirikizumab SC Q4W | Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 64 | 31 | 32 | 64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 64 | 31 | 32 | 64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 59 | 29 | 28 | 60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 2 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Enrollment failure | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | Period 1: 600 mg Mirikizumab IV Q4W | Period 1: 1000 mg Mirikizumab IV Q4W | Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | Period 3: 300 mg Mirikizumab SC Q4W | Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 9 | 9 | 23 | 46 | 30 | 59 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 8 | 8 | 20 | 41 | 24 | 42 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 6 | 17 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pi decision due to lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pi and sponsor decision due to subject safety | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pi decision due to lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Endoscopic procedure was not evaluated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy and withdrew from study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | Period 1: 600 mg Mirikizumab IV Q4W | Period 1: 1000 mg Mirikizumab IV Q4W | Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | Period 3: 300 mg Mirikizumab SC Q4W | Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 137 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 137 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Roll over to amax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 108 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Decided to not participate in extension period (week 104-208) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pi decision as subject not responding to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study visit schedule | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | Period 1: 600 mg Mirikizumab IV Q4W | Period 1: 1000 mg Mirikizumab IV Q4W | Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | Period 3: 300 mg Mirikizumab SC Q4W | Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
Endoscopic response defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12. The SES-CD evaluates 4 endoscopic variables: presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis. The total SES-CD calculated as sum of 4 variables for 5 bowel segments: (ileum;right,transverse,and left colon;and rectum): presence and size of ulcers (none = score 0; diameter 0.1-0.5 cm = score 1; 0.5-2 cm = score 2; \>2 cm = score 3); extent of ulcerated surface (none = 0; \<10% = 1;10-30% = 2;\>30% = 3);extent of affected surface (none = 0; \<50% = 1;50-75% = 2;\>75% =3); and presence and type of narrowings (none=0; single, can be passed=1; multiple,can be passed=2; cannot be passed=3). Total SES-CD scores range from 0 to 56, with higher scores indicating more severe disease.
| percentage of participants | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Response at Week 12 | 10.9 (4.5 to 17.4) | 25.8 (12.9 to 38.7) | 37.5 (23.4 to 51.6) | 43.8 (33.6 to 53.9) |
Endoscopic remission defined as SES-CD of \<4 ileal-colonic or \<2 for isolated ileal disease, and no subscore \>1 at week 12. The SES-CD evaluates 4 endoscopic variables: presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: (ileum; right, transverse, and left colon; and rectum): presence and size of ulcers (none = score 0; diameter 0.1-0.5 cm = score 1; 0.5-2 cm = score 2; greater than (\>) 2 cm = score 3); extent of ulcerated surface (none = 0; less than (\<) 10% = 1; 10-30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50-75% = 2; \>75% = 3); and presence and type of narrowings (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total SES-CD scores range from 0 to 56, with higher scores indicating more severe disease.
| percentage of participants | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Remission at Week 12 | 1.6 (0.0 to 4.1) | 6.5 (0.0 to 13.7) | 15.6 (5.1 to 26.2) | 20.3 (12.0 to 28.6) |
PRO remission is defined as stool frequency (SF) ≤2.5 and abdominal pain (AP) ≤1 and no worse than baseline at week 12. SF captures the number of liquid or very soft stools. AP score is classified as 0=none, 1=mild, 2=moderate, 3=severe.
| percentage of participants | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Percentage of Participants Achieving Patient Reported Outcome Remission at Week 12 | 6.3 (1.3 to 11.2) | 12.9 (3.0 to 22.8) | 28.1 (15.1 to 41.2) | 21.9 (13.4 to 30.4) |
The PGRS is a 1-item patient-rated questionnaire designed to assess the participant's rating of their disease symptom severity over the past 24 hours. Responses are graded on a 6-point scale in which a score of 1 indicates the subject has no symptoms (that is, "none") and a score of 6 indicates that the participant's symptom are "very severe." Least Squares Mean (LS Mean) was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
| score on a scale | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Mean Change From Baseline on the Patient Global Rating - Severity (PGRS) Crohn's Disease Score at Week 12 | -0.44 ± 0.132 | -1.08 ± 0.194 | -1.27 ± 0.189 | -0.98 ± 0.134 |
The PGRC scale is a patient-rated instrument designed to assess the participant's rating of change in their symptom(s). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the participant's symptom is "very much better," a score of 4 indicates that the participant's symptom has experienced "no change," and a score of 7 indicates that the participant's symptom is "very much worse."
| score on a scale | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Mean of Patient Global Rating - Change (PGRC) Crohn's Disease Score at Week 12 | 3.6 ± 1.11 | 2.8 ± 1.26 | 2.6 ± 0.97 | 2.5 ± 0.89 |
The IBDQ is a 32-item self-administered questionnaire. The IBDQ has 4 dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
| score on a scale | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Mean Change From Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 12 | 17.11 ± 3.725 | 41.16 ± 5.311 | 46.57 ± 5.244 | 42.35 ± 3.770 |
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0-4 associated with a range over "Not at all" to "Very much" for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
| score on a scale | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| Mean Change From Baseline on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12 | 2.90 ± 1.209 | 10.81 ± 1.728 | 9.09 ± 1.721 | 9.62 ± 1.223 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains:physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS Mean was calculated using Mixed Model for Repeated Measures (MMRM) model with treatment, geographic region, geographic region, prior biologic CD therapy use (prior biologic experience versus prior biologic naive), baseline score, visit, and the interaction of treatment-by-visit and baseline-by-visit as fixed factors.
| score on a scale | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W |
|---|---|---|---|---|
| MCS | 2.34 ± 1.133 | 7.47 ± 1.602 | 6.52 ± 1.592 | 6.05 ± 1.152 |
| PCS | 3.11 ± 0.774 | 4.70 ± 1.096 | 8.01 ± 1.108 | 6.70 ± 0.787 |
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance. Clearance is estimated based on concentration data collected in the time frame of 0-208 weeks.
| Liters per Hour (L/h) | Mirikizumab IV Q4W |
|---|---|
| Population Pharmacokinetics (PopPK): Mean Population Clearance of Mirikizumab | 0.0225 ± 30 |
Population mean (between-subject coefficient variance \[CV %\]) apparent volume of distribution. Volume of distribution is estimated based on concentration data collected in the time frame of 0-208 weeks.
| Liters (L) | Mirikizumab IV Q4W |
|---|---|
| Population Pharmacokinetics (PopPK): Mean Population Volume of Distribution of Mirikizumab | 5.05 ± 18 |
Collected over Baseline Up To 208 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | 0/64 (0%) | 7/64 (10.9%) | 24/64 (37.5%) |
| Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | 0/31 (0%) | 0/31 (0%) | 11/31 (35.5%) |
| Period 1: 600 mg Mirikizumab IV Q4W | 0/32 (0%) | 3/32 (9.4%) | 12/32 (37.5%) |
| Period 1: 1000 mg Mirikizumab IV Q4W | 0/64 (0%) | 2/64 (3.1%) | 27/64 (42.2%) |
| Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | 0/23 (0%) | 0/23 (0%) | 14/23 (60.9%) |
| Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | 0/46 (0%) | 2/46 (4.3%) | 30/46 (65.2%) |
| Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | 0/30 (0%) | 3/30 (10%) | 16/30 (53.3%) |
| Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | 0/59 (0%) | 9/59 (15.3%) | 30/59 (50.8%) |
| Period 3: 300 mg Mirikizumab SC Q4W | 0/136 (0%) | 15/136 (11%) | 89/136 (65.4%) |
| Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Event | Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | Period 1: 600 mg Mirikizumab IV Q4W | Period 1: 1000 mg Mirikizumab IV Q4W | Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | Period 3: 300 mg Mirikizumab SC Q4W | Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maternal exposure during pregnancyInjury, poisoning and procedural complications | 0/36 | 0/14 | 0/18 | 0/30 | 0/4 | 0/4 | 0/12 | 0/23 | 1/13 | 0/33 | 0/61 | 0/1 | — | 0/1 | 0/1 | 0/1 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/36 | 0/14 | 0/18 | 0/30 | 0/4 | 0/4 | 0/12 | 0/23 | 1/13 | 0/33 | 0/61 | 0/1 | — | 0/1 | 0/1 | 0/1 |
| Crohn's diseaseGastrointestinal disorders | 3/64 | 0/31 | 1/32 | 0/64 | 0/9 | 0/9 | 0/23 | 1/46 | 1/30 | 1/59 | 2/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Anaphylactic reactionImmune system disorders | 0/64 | 0/31 | 0/32 | 0/64 | 0/9 | 0/9 | 0/23 | 0/46 | 0/30 | 2/59 | 0/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| PneumoniaInfections and infestations | 0/64 | 0/31 | 0/32 | 0/64 | 0/9 | 0/9 | 0/23 | 0/46 | 1/30 | 0/59 | 0/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Large intestinal stenosisGastrointestinal disorders | 0/64 | 0/31 | 1/32 | 0/64 | 0/9 | 0/9 | 0/23 | 0/46 | 0/30 | 0/59 | 0/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Large intestine perforationGastrointestinal disorders | 0/64 | 0/31 | 1/32 | 0/64 | 0/9 | 0/9 | 0/23 | 0/46 | 0/30 | 0/59 | 0/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Non-cardiac chest painGeneral disorders | 0/64 | 0/31 | 1/32 | 0/64 | 0/9 | 0/9 | 0/23 | 0/46 | 0/30 | 1/59 | 0/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Paternal exposure during pregnancyInjury, poisoning and procedural complications | 0/28 | 0/17 | 0/14 | 0/34 | 0/5 | 0/5 | 0/11 | 0/23 | 0/17 | 0/26 | 2/75 | — | 0/2 | — | — | 0/2 |
| Ileal perforationGastrointestinal disorders | 0/64 | 0/31 | 0/32 | 0/64 | 0/9 | 0/9 | 0/23 | 1/46 | 0/30 | 0/59 | 0/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Event | Period 1: Placebo Intravenous (IV) Every 4 Weeks (Q4W) | Period 1: 200 Milligram (mg) Mirikizumab IV Q4W | Period 1: 600 mg Mirikizumab IV Q4W | Period 1: 1000 mg Mirikizumab IV Q4W | Period 2: 200 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 600 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Improvers) | Period 2: 300mg Mirikizumab Subcutaneous (SC) Q4W (Period 1 Mirikizumab Improvers) | Period 2: 1000 mg Mirikizumab IV Q4W (Period 1 Mirikizumab Non-improvers) | Period 2: 1000 mg Mirkizumab IV Q4W (Period 1 Placebo) | Period 3: 300 mg Mirikizumab SC Q4W | Follow-up Period: 200 mg Mirikizumab IV Q4W in Period 2 | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Improvers) | Follow-up Period: 1000 mg Mirikizumab IV Q4W in Period 2 (Period 1 Mirikizumab Non-improvers) | Follow-up Period: 1000 mg Mirkizumab IV Q4W in Period 2 (Placebo in Period 1) | Follow-up Period: 300 mg Mirikizumab SC Q4W in Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 6/64 | 0/31 | 0/32 | 0/64 | 0/9 | 0/9 | 1/23 | 3/46 | 0/30 | 1/59 | 8/136 | 0/1 | 0/2 | 1/1 | 0/1 | 0/3 |
| Respiratory tract infection viralInfections and infestations | 1/64 | 1/31 | 0/32 | 0/64 | 0/9 | 0/9 | 0/23 | 1/46 | 0/30 | 1/59 | 2/136 | 0/1 | 0/2 | 1/1 | 0/1 | 0/3 |
| Vitamin d deficiencyMetabolism and nutrition disorders | 0/64 | 0/31 | 0/32 | 0/64 | 0/9 | 0/9 | 0/23 | 0/46 | 2/30 | 0/59 | 0/136 | 0/1 | 1/2 | 0/1 | 0/1 | 0/3 |
| Vulvovaginal mycotic infectionInfections and infestations | 1/36 | 0/14 | 0/18 | 0/30 | 0/4 | 1/4 | 0/12 | 0/23 | 0/13 | 2/33 | 2/61 | 0/1 | — | 0/1 | 0/1 | 0/1 |
| NasopharyngitisInfections and infestations | 1/64 | 0/31 | 2/32 | 4/64 | 0/9 | 0/9 | 2/23 | 6/46 | 3/30 | 4/59 | 25/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| Injection site reactionGeneral disorders | 0/64 | 0/31 | 0/32 | 0/64 | 0/9 | 1/9 | 0/23 | 3/46 | 0/30 | 1/59 | 18/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/64 | 1/31 | 1/32 | 3/64 | 1/9 | 1/9 | 1/23 | 6/46 | 1/30 | 3/59 | 8/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| HeadacheNervous system disorders | 2/64 | 2/31 | 2/32 | 7/64 | 0/9 | 0/9 | 3/23 | 4/46 | 3/30 | 4/59 | 16/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 1/64 | 2/31 | 1/32 | 2/64 | 1/9 | 0/9 | 1/23 | 2/46 | 2/30 | 5/59 | 7/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
| HypothyroidismEndocrine disorders | 0/64 | 0/31 | 0/32 | 0/64 | 0/9 | 1/9 | 0/23 | 0/46 | 0/30 | 0/59 | 1/136 | 0/1 | 0/2 | 0/1 | 0/1 | 0/3 |
All randomized participants.
| Age, Continuous(years) | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Mean | 39.00 ± 13.04 | 38.10 ± 11.80 | 40.40 ± 13.33 | 37.70 ± 13.11 | 38.70 ± 12.70 |
| Sex: Female, Male(Participants) | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Female | 36 | 14 | 18 | 30 | 98 |
| Male | 28 | 17 | 14 | 34 | 93 |
| Ethnicity (NIH/OMB)(Participants) | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 2 | 2 | 8 |
| Not Hispanic or Latino | 53 | 27 | 26 | 54 | 160 |
| Unknown or Not Reported | 7 | 4 | 4 | 8 | 23 |
| Race (NIH/OMB)(Participants) | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 7 | 1 | 4 | 8 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 3 | 4 | 11 |
| White | 55 | 28 | 24 | 52 | 159 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo IV Q4W | 200 mg Mirikizumab IV Q4W | 600 mg Mirikizumab IV Q4W | 1000 mg Mirikizumab IV Q4W | Total |
|---|---|---|---|---|---|
| Australia | 3 | 0 | 0 | 1 | 4 |
| Belgium | 0 | 1 | 1 | 4 | 6 |
| Czechia | 4 | 1 | 0 | 5 | 10 |
| Hungary | 3 | 1 | 0 | 3 | 7 |
| Japan | 6 | 1 | 4 | 7 | 18 |
| Netherlands | 2 | 3 | 0 | 2 | 7 |
| Poland | 6 | 6 | 3 | 9 | 24 |
| Romania | 0 | 0 | 1 | 4 | 5 |
| Russia | 6 | 3 | 2 | 3 | 14 |
| Ukraine | 4 | 5 | 4 | 6 | 19 |
| United Kingdom | 1 | 0 | 0 | 0 | 1 |
| United States | 29 | 10 | 17 | 20 | 76 |
Showing the first 100 of 108 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2016 to primary completion in Dec 2018, 23 months.
Results were first posted in Feb 2022, 3 years 2 months after primary completion. A results delay was requested in Mar 2020.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 23 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab